NASDAQ:ONTX

Onconova Therapeutics Stock Forecast, Price & News

$0.78

-0.05 (-6.02 %)

(As of 01/19/2021 12:00 AM ET)

Add

Compare

Today's Range

$0.74

Now: $0.78▼

$0.82

50-Day Range

$0.31

MA: $0.49▼

$0.83

52-Week Range

$0.19

Now: $0.78▼

$1.56

Volume32.31 million shs

Average Volume61.76 million shs

Market Capitalization$161.26 million

P/E RatioN/A

Dividend YieldN/A

Beta2.03

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

MarketRank^™

Overall MarketRank^™

1.50 out of 5 stars

3.1 Analyst's Opinion

Consensus Rating
Onconova Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.52, Onconova Therapeutics has a forecasted upside of 94.4% from its current price of $0.78.
Amount of Analyst Coverage
Onconova Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Onconova Therapeutics has received 359 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Onconova Therapeutics has received 302 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Onconova Therapeutics has received 54.31% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote “Outperform” if you believe ONTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Onconova Therapeutics does not currently pay a dividend.
Dividend Growth
Onconova Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Onconova Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,837.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.80% of the stock of Onconova Therapeutics is held by insiders.
Percentage Held by Institutions
Only 6.67% of the stock of Onconova Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Onconova Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Onconova Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Onconova Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Onconova Therapeutics has a P/B Ratio of 9.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ONTX

Previous Symbol

CUSIPN/A

CIK1130598

Webwww.onconova.com

Phone267-759-3680

Employees17

Debt

Debt-to-Equity RatioN/A

Current Ratio2.69

Quick Ratio2.69

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.18 million

Price / Sales73.97

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.08 per share

Price / Book9.75

Profitability

EPS (Most Recent Fiscal Year)($1.49)

Net Income$-21,500,000.00

Net Margins-11,997.55%

Return on Equity-161.10%

Return on Assets-89.69%

Miscellaneous

Outstanding Shares206,694,000

Market Cap$161.26 million

Next Earnings Date3/23/2021 (Estimated)

OptionableNot Optionable

$0.78

-0.05 (-6.02 %)

(As of 01/19/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.

Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

How has Onconova Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Onconova Therapeutics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONTX shares have increased by 116.7% and is now trading at $0.7802.
View which stocks have been most impacted by COVID-19.

Is Onconova Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Onconova Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONTX, but not buy additional shares or sell existing shares.
View analyst ratings for Onconova Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Onconova Therapeutics?

Wall Street analysts have given Onconova Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Onconova Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 23rd 2021.
View our earnings forecast for Onconova Therapeutics.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its quarterly earnings results on Thursday, November, 12th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The biopharmaceutical company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $4.10 million. Onconova Therapeutics had a negative net margin of 11,997.55% and a negative return on equity of 161.10%.
View Onconova Therapeutics' earnings history.

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Shares of Onconova Therapeutics reverse split before market open on Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for ONTX?

4 brokerages have issued twelve-month target prices for Onconova Therapeutics' stock. Their forecasts range from $1.25 to $2.00. On average, they expect Onconova Therapeutics' stock price to reach $1.52 in the next twelve months. This suggests a possible upside of 94.4% from the stock's current price.
View analysts' price targets for Onconova Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Onconova Therapeutics' key competitors?

Some companies that are related to Onconova Therapeutics include Chinook Therapeutics (KDNY), Basilea Pharmaceutica (BPMUF), Rigel Pharmaceuticals (RIGL), BELLUS Health (BLUSF), Veru (VERU), Relmada Therapeutics (RLMD), Ardelyx (ARDX), Inozyme Pharma (INZY), Affimed (AFMD), Akouos (AKUS), Homology Medicines (FIXX), Flexion Therapeutics (FLXN), Molecular Templates (MTEM), BioVie (BIVI) and Five Prime Therapeutics (FPRX).
View all of ONTX's competitors.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the following people:

Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 69, Pay $722.51k)
Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 57, Pay $565.31k)
Dr. Richard Charles Woodman M.D., Chief Medical Officer and Sr. VP of R&D (Age 65, Pay $405.31k)
Dr. Ramesh Kumar, Advisor (Age 64, Pay $1.21M)
Mr. Mark Patrick Guerin, Chief Financial Officer (Age 51)
Mr. Abraham N. Oler J.D., M.B.A., Esq., CFA, Sr. VP of Corp. Devel. & Gen. Counsel (Age 44)

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.78.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $161.26 million and generates $2.18 million in revenue each year. The biopharmaceutical company earns $-21,500,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Onconova Therapeutics employs 17 workers across the globe.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is www.onconova.com.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]

This page was last updated on 1/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here